Long-term survival and reason for revision of Wagner resurfacing hip arthroplasty.

J Arthroplasty

The Department of Orthopedics and Trauma, Royal Adelaide Hospital, University of Adelaide, North Terrace, Adelaide, South Australia, Australia.

Published: June 2010

The long-term survival of 270 Wagner resurfacing hip arthroplasties was determined. Two patients were lost to follow-up. Eleven hips remained unrevised at 15 to 22 years. Survival at 5, 10, and 16 years was 74%, 35%, and 17%, respectively. Survival in patients older than 55 years was better after 5 years than that for patients 55 years or younger (P = .0067). Femoral neck fracture occurred in 2% of the total cohort. Femoral component failure was an early and midterm complication. Acetabular component loosening was the most common reason for revision. The proportion of cases revised for acetabular component failure increased with time. These long-term data in this large series provide important historical results against which the relative benefits of contemporary designs may be evaluated.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.arth.2009.04.007DOI Listing

Publication Analysis

Top Keywords

long-term survival
8
reason revision
8
wagner resurfacing
8
resurfacing hip
8
component failure
8
acetabular component
8
years
5
survival reason
4
revision wagner
4
hip arthroplasty
4

Similar Publications

Background: Glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment reduces cardiovascular events in type 2 diabetes. Yet, the impact of GLP-1RA treatment before ST-segment elevation myocardial infarction (STEMI) on long-term prognosis in patients with type 2 diabetes remains unclear. In patients with STEMI and type 2 diabetes, we aimed to investigate the association between long-term prognosis and GLP-1RA treatment before STEMI.

View Article and Find Full Text PDF

Background: The Bahçeşehir population-based mammography screening program (BMSP) is an example of Türkiye's first population-based screening program. This study aims to reveal the successful implementation of population-based secreening program in one of the low- and middle-income countries, Türkiye and long-term results of patients diagnosed with breast cancer during BMSP.

Methods: This study was conducted between 2009 and 2019, in the Bahçeşehir county of Istanbul.

View Article and Find Full Text PDF

Economic burden of Type 2 diabetes in Iran in 2022.

BMC Public Health

January 2025

Department of Health Management, Policy & Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.

Background: Diabetes mellitus, particularly Type 2 diabetes (T2D), represents a significant global health challenge, with its prevalence steadily rising over the past few decades. This study was conducted with the aim of estimating the economic burden of T2D in Iran.

Methods: This study employed a prevalence-based approach to estimate the economic burden of T2D and its attributable complications in adults above 20 years old in Iran for 2022.

View Article and Find Full Text PDF

Background: Immune checkpoint inhibitors (ICIs) are recommended to treat patients with deficient mismatch repair/microsatellite instability high (dMMR/MSI-H) metastatic colorectal cancer (mCRC). Pivotal trials have fixed a maximum ICI duration of 2 years, without a compelling rationale. A shorter treatment duration has the potential to improve patients' quality of life and reduce both toxicity and cost without compromising efficacy.

View Article and Find Full Text PDF

Overall and late mortality among 24 459 survivors of adolescent and young adult cancer in Alberta, Canada: a population-based cohort study.

Lancet Public Health

January 2025

Department of Oncology, University of Calgary, Calgary, AB, Canada; Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada; Department of Cancer Epidemiology and Prevention Research, Cancer Care Alberta, Alberta Health Services, Arthur Child Comprehensive Cancer Centre, Calgary, AB, Canada. Electronic address:

Background: Adolescent and young adult (AYA) cancer survivors are at an increased risk of premature mortality due to their cancer and its treatment. Herein, we aimed to quantify the excess risks of mortality among AYA cancer survivors and identify target populations for intervention.

Methods: The Alberta AYA Cancer Survivor Study is a retrospective, population-based cohort of individuals diagnosed with a first primary neoplasm at age 15-39 years in Alberta, Canada, between 1983 and 2017.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!